Towards Healthcare
Non-Invasive Prenatal Testing Market to Lead USD 18.94 Bn by 2034

Non-Invasive Prenatal Testing Market Analysis and Forecast 2025 to 2034

Based on market forecasts, the non-invasive prenatal testing sector will expand from USD 6.45 billion in 2024 to USD 18.94 billion by 2034, experiencing a CAGR of 11.65%. The non-invasive prenatal testing market is growing due to the increasing demand for safer, earlier, and accurate detection of fetal genetic disorders. North America is dominating due to the rising demand for genetic screening.

  • Insight Code: 6222
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: September 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

FAQ's

The non-invasive prenatal testing market stands at USD 7.2 billion in 2025 and is expected to reach USD 18.94 billion by 2034, growing at a CAGR of 11.65% from 2024 to 2034.

North America is currently leading the non-invasive prenatal testing market share by 40% due to rising research in the testing process.

The non-invasive prenatal testing market includes five segments by test type, by technology, by application, by end-user, and by region.

Some key players include Illumina, Natera, Roche, Fulgent Genetics, Berry Genomics, Invitae, etc.

FDA, WHO, UNICEF, National Institutes of Health, CDC, PIB, etc.